Phase 4Active, not recruiting

Finerenone Plus SGLT2 Inhibitors in Heart Failure (FIN-SGLT2-HF)

Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure

Sponsor
Mansoura University (Academic or other)
Enrollment
60 planned
Conditions
Heart Failure
Interventions
Finerenone; dapagliflozine
Ages
adults, older adults
Registry
NCT07351864

Full record on ClinicalTrials.gov

From the registry

The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.

Primary outcomes

  • Cardiovascular Mortality and Heart Failure Hospitalization

History

  1. Primary completion

  2. Last registry update

  3. Registered

  4. Started